# Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN

> **NCT03878979** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 26 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer
- Head and Neck Cancer Metastatic

## Interventions

- **DRUG:** Nivolumab 480mg and surgical resection

## Key facts

- **NCT ID:** NCT03878979
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-08
- **Primary completion:** 2023-10-17
- **Final completion:** 2023-10-17
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878979, "Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03878979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*